Polyethylene glycol-coated haemostatic patch for prevention of clinically relevant postoperative pancreatic fistula after pancreatoduodenectomy: randomized clinical trial

• Published in: BJS open Vol. 7; no. 2
• Main Authors: Serradilla-Martín, Mario, Paterna-López, Sandra, Palomares-Cano, Ana, Cantalejo-Díaz, Miguel, Abadía-Forcén, Teresa, Gutiérrez-Díez, Marta L, Artigas-Marco, Consuelo, Serrablo-Requejo, Alejandro
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 07.03.2023
• Subjects: Hemostatics; Humans; Pancreas; Pancreatic Fistula - etiology; Pancreaticoduodenectomy - adverse effects; Pancreaticojejunostomy - adverse effects; Postoperative Complications - etiology; Randomized Clinical Trial
• ISSN: 2474-9842; 2474-9842
• DOI: 10.1093/bjsopen/zrad028

Abstract Background The potential of haemostatic patches to reduce the rate of postoperative pancreatic fistula remains unclear. The aim of this trial was to evaluate the impact of a polyethylene glycol-coated haemostatic patch on the incidence of clinically relevant postoperative pancreatic fistula after pancreatoduodenectomy. Methods In this randomized, single-centre, clinical trial, patients undergoing pancreatoduodenectomy were randomized 1 : 1 to receive pancreatojejunostomy reinforced with two polyethylene glycol-coated haemostatic patches (patch group) or without any reinforcement (control group). The primary outcome was clinically relevant postoperative pancreatic fistula, defined as grade B/C according to International Study Group of Pancreatic Surgery criteria, within 90 days. Key secondary outcomes were length of hospital stay, total rate of postoperative pancreatic fistula, and overall complication rate. Results From 15 May 2018 to 22 June 2020, 72 patients were randomized, and 64 were included in the analyses (31 in the patch group and 33 in the control group). The risk of clinically relevant postoperative pancreatic fistula was reduced by 90 per cent (OR 0.10, 95 per cent c.i. 0.01 to 0.89, P = 0.039). Moreover, the use of the polyethylene glycol-coated patch retained its protective effect on clinically relevant postoperative pancreatic fistula in a multivariable regression model, significantly reducing the risk of clinically relevant postoperative pancreatic fistula by 93 per cent (OR 0.07, 95 per cent c.i. 0.01 to 0.67, P = 0.021), regardless of patient age, sex, or fistula risk score. The incidence of secondary outcomes did not significantly differ between the groups. One patient died within 90 days in the patch group versus three patients in the control group. Conclusions A polyethylene glycol-coated haemostatic patch reduced the incidence of clinically relevant postoperative pancreatic fistula after pancreatoduodenectomy. Registration number NCT03419676 (http://www.clinicaltrials.gov). Hemopatch™ significantly reduced the incidence of clinically relevant postoperative pancreatic fistula in patients who underwent a pancreatoduodenectomy. The effectiveness of the patch was related to the fistula risk score.